Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

Fig. 2

Proportion of patients achieving clinical success by day 2 and day 3: overall (a), by infection type (b), and by pathogen (c). Clinical success was defined as improvement or cure. a Odds ratio (OR) for vancomycin compared with daptomycin. b Clinical success rates by infection type, excluding the 4 daptomycin and 4 vancomycin patients with “other” infection types. c Clinical success rates by pathogen, includr known S. aureus infection for those patients with a culture. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus. See Table 3 for sample sizes

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us